Connect with us

Technology

Bank Hapoalim Announces 2026 Third Quarter Results

Published

on

Net profit in 3Q26 totaled NIS 2,364 million; return on equity 14.0%. Net profit in the first nine months of 2026 totaled NIS 6,976 million; return on equity 14.0%.The annual impact of the special tax on banks is 1.3%–1.4%. Excluding the tax impact, ROE for both 3Q26 and 9M26 was approximately 15.4%.Total income decreased 6.7% vs. the previous quarter, mainly due to less favorable macroeconomic factors and softer capital-market activity. However, income from regular financing activity excluding the CPI impact increased by 1.7% in the nine-month period.Total expenses were down 1.8% QoQ and 3.4% YoY; the cost-income ratio was 32.2% in the quarter and 32.9% in the nine-month period.Credit growth was strong and diversified across all segments of operation, at 3.2% QoQ and 15.4% YoY.Credit quality metrics remained strong: the NPL ratio was 0.49% and the NPL coverage ratio was 292%. The credit-loss ratio decreased to 0.12% in the quarter, reflecting a lower collective provision driven by improved risk parameters and more favorable macroeconomic forecasts.Shareholders’ equity continued to grow organically, up 5.9% over the last twelve months, despite the impact of the increase in U.S. and Israel government yield curves. The CET-1 capital ratio was 11.62%, vs. a minimum internal target of 11.0%.The board of directors declared a total distribution of 50% of net profit, of which a cash dividend of NIS 946 million, with the remainder through the execution of the first tranche of a newly launched share buyback plan (NIS 236 million).

TEL AVIV, Israel, Nov. 16, 2026 /PRNewswire/ — Bank Hapoalim (TASE: POLI) today announced its financial results for the third quarter ended September 30, 2026.

Income statement 

Net profit in the third quarter of 2026 totaled NIS 2,364 million, compared with NIS 2,488 million in the preceding quarter and NIS 2,758 million in the same quarter last year. Net profit in the corresponding quarter included one-time income of NIS 380 million, net, from an insurance reimbursement. Excluding this income, 2025 third-quarter net profit amounted to NIS 2,378 million. 
The decrease in 3Q26 net profit vs. the comparable quarters was mainly driven by a less favorable interest-rate and inflation environment and a decrease in non-regular financing activity, partially offset by continued growth in business activity, higher fees, lower operating expenses, and lower credit-loss provisions.Income from regular financing activity in 3Q26 (NIS 4,819 million vs. NIS 5,109 million in 2Q26) was negatively impacted by lower interest rates (3.45% vs. 3.91%, on average) and CPI (1.0% vs. 1.3% known CPI), and lower income from regular non-interest financing activity, due to lower volatility and trading volumes in capital markets.The financial margin from regular activity was 2.55% in the third quarter, vs. 2.70% in the preceding quarter, reflecting lower interest rates and CPI, as well as lower regular capital-market activity. Income from non-regular financing activity totaled NIS 28 million in the third quarter, vs. NIS 325 million in the preceding quarter. The decrease was driven by substantially lower income from equity investments, amid softer equity markets, as well as realized losses on AFS bonds.Fee income totaled NIS 1,277 million in the third quarter, compared with NIS 1,145 million in the previous quarter and NIS 1,117 million in the same quarter last year. Third-quarter fees benefited from financing-related fee income recognized following a reimbursement from insurers in respect of Sale Law guarantee insurance. Credit-handling fees also grew, reflecting the recognition of syndication fees from infrastructure transactions, as the bank led the financing of one of Israel’s largest energy infrastructure projects in recent years during the quarter.
Fees for the nine-month period grew 6.5% to NIS 3.5 billion. Excluding one-time income recorded in both periods, growth was broadly similar and distributed across all fee types.Operating and other expenses totaled NIS 1,982 million in the third quarter, compared with NIS 2,019 million in the previous quarter and NIS 2,052 million in the same quarter last year, a decrease of 1.8% QoQ and 3.4% YoY. On the longer view of the nine-month period, operating and other expenses declined by 2.2%, due to a decline in both other expenses and salary expenses. Salary expenses declined by 3.1% due to lower bonus provisions, while base salary expenses remained stable, supported by efficiency measures and employee retirements.The cost-income ratio remained low at 32.2% in the third quarter of 2026 and was 32.9% for the first nine months of 2026.The provision for credit losses in the third quarter of 2026 totaled NIS 167 million (a credit-loss ratio of 0.12%). The low provision for credit losses is due to a decrease in the collective provision, which reflects improved risk parameters and more favorable macroeconomic forecasts. The individual provision remained low at NIS 31 million, with no exceptional recoveries during the quarter.Profit before tax for the nine-month period remained stable at NIS 11.8 billion, and even grew by 3.7% excluding the aforementioned one-time income in the corresponding period, despite a decline of approximately 70 basis points in interest rates and lower CPI (2.1% in the first nine months of 2026, vs. 3.0% in the corresponding period last year). This reflects continued growth in the bank’s business activity, lower credit loss provisions, and a 2.2% reduction in operating expenses. Profit after tax for the nine-month period was negatively impacted by the special tax imposed on Israeli banks. The special tax on the banking industry increased from NIS 1.3 billion in 2025 to approximately NIS 3.0 billion in 2026. For Bank Hapoalim, the special tax is approximately NIS 950 million in 2026 and approximately NIS 40 million in 2027.

Balance sheet

Net credit to the public in the third quarter of 2026 totaled NIS 553.2 billion, compared with NIS 536.2 billion in the preceding quarter, an increase of 3.2%. Compared with the corresponding quarter, net credit to the public increased by 15.4%. The growth in the credit portfolio was broad-based across all segments of operation and diversified across several economic sectors. Corporate credit increased by 3.4% in comparison to the preceding quarter, and by 27.5% in comparison to the corresponding quarter; commercial credit increased by 5.3% QoQ and 16.7% YoY. In the retail banking division, the housing loan portfolio grew by 1.8% QoQ and 6.3% YoY, small business credit increased by 2.0% and 8.9%, and consumer credit grew by 1.8% and 7.0%, respectively.Total deposits reached NIS 637.2 billion, an increase of 3.1% vs. the last quarter and 7.9% vs. the same quarter last year. Retail deposits stayed fairly flat vs. comparable periods, at NIS 318.1 billion, constituting 50% of total deposits.LCR and NSFR are at 126% and 115% respectively, vs. the minimum regulatory requirement of 100%. The allowance for credit losses stood at NIS 9.1 billion as at September 30, 2026, of which NIS 8.7 billion attributed to the collective allowance. The total allowance constitutes 1.61% of total credit.Credit quality indicators remained strong; the NPL ratio stood at 0.49% and the NPL coverage ratio (balance sheet allowance for credit losses/NPL) was 292%.Shareholders’ equity grew by 5.9% in the last year, to NIS 67.5 billion, supported by our strong organic capital generation, partially offset by a decrease in the balance of the capital reserve in respect of the AFS bond portfolio. The CET-1 capital ratio stood at 11.62%, vs. the 10.24% minimum regulatory requirement and 11.0% minimum internal target, as at September 30, 2026. The total capital ratio as at September 30, 2026, stood at 14.09%, vs. a 13.5% minimum regulatory requirement.Dividend distribution and share buyback: The board of directors declared a distribution at an overall rate of 50% of net profit, of which a cash dividend of NIS 946 million and the rest through the exercise of the first tranche of a new share buyback plan (NIS 236 million). The dividend will be paid on December 1, 2026.

Financial targets

Financial targets for 2026–2027, based on baseline assumptions as of March 5, 2026, and following the completion on March 30, 2026, of the legislation regarding a special bank tax in 2026 and 2027:

Net profit in the range of NIS 8.5–9.5 billion for 2026 and NIS 9.5–10.5 billion for 2027;Return on equity in the range of 13%–14% for 2026 and 14%–15% for 2027;Growth of the credit portfolio at an average annual rate of 8%–9%;Profit distribution at a rate of 50%–60% of net profit, through cash dividends or buybacks, subject to the guidelines of the Bank of Israel.

Recent developments

Annual general meeting of shareholders
On October 29, 2026, the bank held its annual general meeting of shareholders for 2026, at which the following resolutions were passed: (1) the Financial Statements and the Report of the Board of Directors and Board of Management of the Bank for 2025 were discussed; (2) the reappointment of Somekh Chaikin (KPMG), CPA, and Ziv Haft (BDO), CPA, as joint auditors of the bank until the end of the next annual general meeting was approved; (3) the appointment of Michal Halperin and Tamar Schechter as external directors pursuant to the Companies Law (for a second and first term of office, respectively) was approved; (4) the appointment of Israel Trau as an other (non-external) director (for a third term of office) was approved; (5) the remuneration policy for officers of the bank was approved; (6) updated terms of service for the bank’s directors, in connection with the grant of fixed equity compensation, were approved; and (7) updated terms of service and employment for the Bank’s CEO, Yadin Antebi, were approved.
As part of the approved remuneration resolutions (items 5 and 7), and as part of a bank-wide initiative to discontinue early retirement arrangements, the option for senior executives to convert their accrued retirement rights into bank shares was also approved.
The bank estimates that the conversion of the accrued retirement rights will result in a one-time expense of approximately NIS 8 million. At the same time, discontinuing the accrual of early retirement and enhanced severance rights and converting them into the bank’s shares is expected to reduce future expenses (service cost and interest) by approximately NIS 10 million per year.

Bank shares buyback plan
On November 19, 2025, the board of directors of the bank (after receiving the approval of the Banking Supervision Department) approved a plan for a buyback of shares of the bank, at a volume not to exceed NIS 1 billion, until November 5, 2026, or until the full amount of the plan was acquired, whichever was earlier. Within this plan, which was completed on September 17, 2026, the bank purchased a cumulative 13,128,375 ordinary shares of the bank, constituting approximately 0.98% of the issued and paid-up capital of the bank, at a total cost of approximately NIS 985 million.
On November 15, 2026, the board of directors of the bank approved a new plan for a buyback of shares of the bank at a volume not to exceed NIS 1 billion, from November 17, 2026, until November 1, 2027, or until the full amount of the plan is acquired, whichever is earlier.

Conference-call/webinar information

Bank Hapoalim will host a conference call/webinar today to discuss the results. The call will take place at 5:00 p.m. Israel time / 3:00 p.m. UK time / 10:00 a.m. Eastern time. Participation in the call/webinar is available via the following link: BankHapoalimQ3.2026 (pre-registration is also available via the link). No password or access code is required. The review will be conducted in listen-only mode, followed by a Q&A session.

The webinar will be accompanied by a presentation, which will be published on the day of the financial statements’ release on the distribution website of the Israel Securities Authority (MAGNA), the Tel Aviv Stock Exchange website, and the bank’s Investor Relations page (Financial Information section) at: https://www.bankhapoalim.com.

A recording of the conference call/webinar will be available one business day following the event, on the bank’s Investor Relations page at the above-mentioned address.

Please note: The conference call is not a substitute for the perusal of the immediate reports and the financial statements of the bank, including all forward-looking information included therein, in accordance with Section 32A of the Israeli Securities Law, 1968.

Contact info:

Tamar Koblenz
Head of Investor Relations
Investor.Relations@poalim.co.il

Dr. Sharona Mazalian-Levi
Spokesperson
sml@poalim.co.il

This press release contains forward-looking statements, as defined in the Israeli Securities Law, relating to future events or future performance.

This press release is provided for convenience purposes only and does not constitute a substitute for a full review of the Bank’s latest periodic/quarterly reports, as filed with the Israel Securities Authority.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bank-hapoalim-announces-2026-third-quarter-results-302940204.html

SOURCE Bank Hapoalim

Continue Reading

Technology

Circular Genomics Advances CircPath™ and Presents Comprehensive Circular RNA Blood Biomarker Data for Early Alzheimer’s Detection and Prediction at CTAD 2026

Published

on

By

Landmark NIH-funded study across nearly 2,400 participants validates circular RNA as a dynamic new molecular intelligence layer, capturing active changes across multiple neurodegenerative pathways years before cognitive decline:

Superior Progression Prediction: Demonstrates a 2.92 Hazard Ratio for predicting symptom onset, 61% stronger than pTau217 alone.Synergistic Performance: Achieves a 4.83 Hazard Ratio for progression and a 0.967 AUC for Alzheimer’s (AD) diagnosis when combined with pTau217, elevating the current standard of care.Crucial Early Window: Detects dynamic molecular divergence before clinical cognitive decline begins.Consistent performance: Delivers consistency for Alzheimer’s disease diagnosis across ancestries.

SAN DIEGO, Nov. 20, 2026 /PRNewswire/ — Circular Genomics, a precision neurology company decoding the dynamic biology of the brain through circular RNA (circRNA) blood biomarkers, today announced the successful presentation of a featured biotech showcase and five comprehensive data posters at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference. Grounded in a landmark NIH-funded study across nearly 2,400 participants, the presented data validates circRNA as a powerful new molecular intelligence layer that predicts Alzheimer’s disease progression years before clinical symptoms emerge.

For over a decade, Alzheimer’s blood diagnostics have relied on measuring single proteins, such as amyloid and tau, which can accumulate silently for decades. Circular Genomics is introducing a fundamentally new category of biomarker. Circular RNAs are highly stable, closed-loop RNA molecules that are enriched in the brain and cross the blood-brain barrier into the bloodstream. Because they reflect active, real-time gene regulation, circRNAs offer a dynamic window into multiple, interconnected brain biological pathways simultaneously, providing researchers with actionable insights into when cognitive symptoms are likely to begin.

Advancing Diagnostics, Prognostics, and Therapeutics 

During the CTAD Biotech Showcase, Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics, delivered a featured presentation on “Next-Generation circRNA Blood Biomarker Platform for Alzheimer’s Disease Detection, Progression Prediction, and Clinical Deployment”. Dr. Mellios highlighted how the CircPath™ platform, currently available for Research Use Only (RUO), is transforming biopharma clinical trials.

“While amyloid and tau tell us the underlying structural pathology is present, they don’t capture the real-time biological response of the brain,” said Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. “By measuring dynamic synaptic, inflammatory, and metabolic changes before symptoms appear, our 34-circRNA signature captures the active and dynamic disease state. When we combine this multi-pathway RNA signal with established markers like pTau217, we achieve a combined hazard ratio over 5. This provides a highly scalable tool to ensure presymptomatic prevention trials are populated with precisely the right patients at the optimal time for intervention; so that, drug developers can drastically improve patient selection and clinical trial efficiencies.”

By delivering whole-transcriptome profiling and targeted prognostic applications, the platform empowers drug developers to de-risk neurological clinical trials. Clinically, this means trial sponsors can now stratify biologically heterogeneous patient cohorts, enrich prevention trials with individuals who are imminently progressing toward cognitive decline, and track multi-pathway pharmacodynamic responses to new therapies from a routine blood draw.

Comprehensive Scientific Evidence Across Poster Presentations 

The five posters presented at CTAD 2026 offered a holistic view of Circular Genomics’ rigorously validated science. Evaluated across three independent cohorts totalling nearly 2,400 individuals, the comprehensive data demonstrated that the company’s proprietary 34-circRNA signature captures dynamic changes in multiple disease pathways providing prognostic information well beyond the identification of Alzheimer’s pathology alone.

Beyond the progression and biological deep dives highlighted below, the posters also confirmed the platform’s exceptional analytical robustness and disease specificity. Research demonstrated that the 34-circRNA signature maintains high specificity for Alzheimer’s disease when measured against non-AD dementias like Parkinson’s disease, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). Furthermore, orthogonal PCR evaluations proved that this blood-based signal can be reliably and consistently measured using quantitative and digital droplet PCR, ensuring the technology is highly scalable for future clinical laboratory deployment.

Highlighted Poster Presentations

Poster P274: Brain-enriched Circular RNAs as Blood-based Biomarkers for Detection of Alzheimer’s Disease-related Biology Across the Disease Continuum

This study examined exactly when circRNA levels shift in relation to clinical disease onset, analyzing a longitudinal cohort of 688 cognitively unimpaired (CU) individuals from the Knight ADRC discovery cohort.

The Science: The 34-circRNA signature detects molecular divergence 4 to 8 years before clinical symptoms emerge, with the most significant shifts occurring 2 to 4 years prior to the onset of cognitive decline.The Outcome: The circRNA model achieved a 0.870 AUC for 5-year progression prediction, drastically outperforming plasma pTau217 (0.676 AUC) and amyloid PET (0.643 AUC). This translates to a notable improvement in predictive accuracy over standard protein tests, giving researchers a crucial early-intervention window to treat patients before irreversible memory loss occurs.

Poster P314: Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer’s Disease: ADRC and A4/LEARN Cohort Replication

To validate the reliability of the prognostic signal, Circular Genomics evaluated the fixed 34-circRNA model across two entirely independent, large-scale replication cohorts: a second Knight ADRC cohort (N=551) and the A4/LEARN study (N=318).

The Science: The prediction of progression from cognitively unimpaired to symptomatic Alzheimer’s disease successfully replicated across both cohorts. The model achieved a remarkable 3.83 Hazard Ratio (HR) in the Knight ADRC replication and a 2.93 HR in the A4/LEARN cohort.The Outcome: The data proves that circRNA elevates existing standard-of-care diagnostics performance. When combined with pTau217, the integrated biomarker model pushed the predictive hazard ratio to an unprecedented 5.58 in the Knight ADRC cohort and 4.58 in the A4/LEARN cohort. This synergistic approach drastically reduces cohort heterogeneity, ensuring pharmaceutical sponsors can identify the exact patients most likely to progress during a trial window.

Poster P313: Alzheimer’s Disease Specificity and Consistent Performance of a Circular RNA Blood-Based Biomarker Model Across Diverse Populations This abstract evaluated the 34-circRNA model to ensure it maintains robust performance across diverse genetic ancestries.

The Science: The signature’s performance remains highly consistent across diverse genetic ancestries: including African American, Hispanic, and Asian populations, as well as across sexes and APOE4 genetic statuses.The Outcome: The research confirms that the circRNA signature delivers equitable, highly specific Alzheimer’s disease detection (maintaining an AUC > 0.90 across diverse populations). This ensures broad clinical applicability for underrepresented groups without sacrificing performance driven by genetic ancestry or non-AD dementias.

The robust data presented at CTAD 2026 cements circular RNA as a transformative, complementary layer of molecular intelligence that elevates the current standard of care. While the CircPath™ platform is currently empowering biopharma partners and academic researchers to de-risk clinical trials and track pathway-level disease activity and responses, this comprehensive validation lays the essential groundwork for future clinical diagnostic deployment. By providing a non-invasive window into the brain’s active biology, Circular Genomics is advancing a future where complex neurodegenerative conditions, starting with Alzheimer’s disease and expanding into Parkinson’s disease and ALS, are measurable, manageable, and treatable years before irreversible cognitive decline alters patients’ lives.

About Circular Genomics

Circular Genomics is a precision medicine company developing circular RNA-based diagnostics and therapeutics to transform the understanding and treatment of neuropsychiatric and neurodegenerative conditions. By leveraging novel RNA biology through its proprietary CircPATH™ platform, the company aims to enable earlier detection, more precise patient stratification, and more targeted interventions across brain health. Circular Genomics is headquartered in San Diego, CA. For more information, visit www.circulargenomics.com.

About CircPATH™

CircPATH™ is Circular Genomics’ proprietary end-to-end circular RNA discovery and validation engine, serving as the technological backbone for all of the company’s diagnostic product offerings. The platform systematically identifies disease-relevant circRNAs from complex biological samples, validates their performance across independent cohorts, and translates them into clinically actionable biomarker panels. By leveraging the unique biology of circular RNAs—their stability, tissue specificity, and functional independence from linear transcripts—CircPATH™ unlocks biomarker signals that have remained invisible to conventional approaches. The platform’s ability to discover brain-enriched circRNAs detectable in blood creates a non-invasive window into central nervous system biology, enabling applications across the full spectrum of neurodegenerative and neuropsychiatric conditions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/circular-genomics-advances-circpath-and-presents-comprehensive-circular-rna-blood-biomarker-data-for-early-alzheimers-detection-and-prediction-at-ctad-2026-302944589.html

SOURCE Circular Genomics

Continue Reading

Technology

Headliners Summit Launches Global Leadership Platform in Miami

Published

on

By

Brings together global leaders from government, business, investment, technology, sport and culture to discuss global growth, investment and innovationThe invitation-only convening encourages critical thought that leads to dynamic actionThe annual event will align with the G20 calendar and will take place in London, England in 2027 and Seoul, Korea in 2028

MIAMI, Nov. 20, 2026 /PRNewswire/ — Headliners Summit today announced the speakers at its inaugural edition, Headliners Miami 2026, taking place on December 16 immediately following the G20. The invitation-only global leadership forum will bring together 400 leaders from government, business, investment, technology, sport, and culture and create a platform for critical thinking and dynamic action.

Headliners Summit centers on direct exchanges and meaningful conversation between leaders across a variety of sectors and markets. The single-room format will combine in-depth interviews and focused discussions addressing topics impacting global economies and the era-defining sectors that increasingly intersect. Attendance is only by invitation and application.

Headliners Summit programming examines the connections between capital, artificial intelligence, energy and infrastructure, alongside developments in commercial space, global security, business, sports and culture. Discussions will explore how these fields shape one another, including the power and data infrastructure required for advances in AI.

Speakers include U.S. Secretary of State Marco Rubio; U.S. Secretary of Treasury Scott Bessent; Roger Goodell, Head of the National Football League; Dina Powell McCormick, President of Meta; U.S. Director of National Intelligence Jay Clayton; Greg Brockman, President and Co-Founder of Open AI; Ken Griffin, CEO of Citadel; Antonio Gracias, Founder and CEO, Valor Equity Partners; Craig Robins, Founder and President, Dacra; and several others. On-stage interviews will be conducted by award-winning journalist Bret Baier and the 43rd Mayor of Miami Francis Suarez.

“We are launching Headliners Summit to build an enduring global forum where leaders from across important sectors can engage directly on the decisions shaping the future,” said Francis Suarez and Bret Baier. “From the program of speakers to the audience of decisionmakers, the focus is on pairing critical thinking with dynamic action.”

Headliners Summit is organized around the belief that serious conversations take place when leaders from a cross-section of fields share their expertise and experience with a focused and receptive audience poised to act. The inaugural edition in Miami is the beginning of Headliners Summit’s recurring annual forum connecting leaders and sectors.

About Headliners

Headliners is an invitation-only global leadership forum built around candid conversation and connections across government, capital, technology, energy, infrastructure, space, business and culture. Its inaugural summit will take place in Miami on December 16, 2026, hosted by Francis Suarez, with headline interviews conducted by Bret Baier. For more information, visit www.headlinerssummit.com.

Media Contact:
Headliners Summit
Susan Ainsworth
susan@ainsworthassociates.net
+1-917-861-7949

View original content to download multimedia:https://www.prnewswire.com/news-releases/headliners-summit-launches-global-leadership-platform-in-miami-302946219.html

SOURCE Headliners

Continue Reading

Technology

Golf Legend Annika Sörenstam Talks with Consello’s Declan Kelly About Pushing Past Our Limits

Published

on

By

NEW YORK, Nov. 20, 2026 /PRNewswire/ — In the latest episode of Grey Matter, eight-time LPGA Player of the Year Annika Sörenstam joins Consello Founder, Chairman, and CEO Declan Kelly to discuss how she continued to push past her own limits long after reaching No. 1 in the world.

Sörenstam built, over the course of her professional career, one of the most distinguished records in the history of golf, winning 10 major championships and 72 LPGA Tour events. Even at the height of her success, she remained convinced that she could always improve. In conversation with Kelly, she reflects on why she was never afraid to set ambitious goals, even when she fell short of them, because they helped her discover what she was capable of.

That conviction produced some of the defining moments of her career, including her record round of 59 in 2001, when she set out to birdie every hole, and her decision in 2003 to compete in the PGA Tour’s Colonial. It also governed how Sörenstam prepared, as she recorded every aspect of her game well before the practice became standard. Through that disciplined system of practice, fitness, nutrition, sleep, and mental preparation, she built the foundation for her dominance.

Sörenstam also speaks with candor about the personal side of her career, including overcoming a deep fear of public speaking and her decision to retire from golf while still at the top of the game. The full episode is available at Consello.com and on YouTube, Spotify, and Apple Podcasts.

About Consello

Consello is an Advisory and Investing Platform with offices in New York, Miami, Atlanta, Dublin, Belfast, London, Brussels, and Abu Dhabi.

Consello’s distinct advisory practices provide the complete strategic counsel today’s leaders need to grow and transform their organizations. Consello’s advisory expertise spans Corporate Advisory; M&A; Management Consulting; Talent; and Sports and Entertainment. Dedicated teams operate in each practice, led by a leadership group with deep operational experience across industries, business growth stages and market cycles and with an expansive set of global corporate relationships.

Consello’s investment business, Consello Capital, identifies high-potential mid-market companies and invests capital and expertise to transform their growth.

Consello Media Inquiries
media@consello.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/golf-legend-annika-sorenstam-talks-with-consellos-declan-kelly-about-pushing-past-our-limits-302946294.html

SOURCE Consello

Continue Reading

Trending